Skip to main content

Advertisement

SpringerLink
Log in

Ocular pulse amplitude and retinal vessel caliber changes after intravitreal ranibizumab

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The purpose of the present study was to examine the effects of intravitreal ranibizumab on ocular pulse amplitude (OPA) and retinal vessel caliber (RVC) in wet age-related macular degeneration (AMD). Thirty-two eyes of 32 wet AMD patients were included in this case series. Three consecutive monthly injections of ranibizumab were performed. The OPA was measured with the Pascal dynamic contour tonometer. RVC measurements were taken with spectral-domain optical coherence tomography. Pre-injection mean OPA value was 2.55 ± 0.76 mmHg and post-injections mean OPA value was 2.79 ± 0.88 mmHg at the last visit (p = 0.10). Pre-injection mean arteriole and venule RVC were 96.7 ± 9.4 and 125.9 ± 8.4 µm; while post-injections arteriole and venule RVC were 96.0 ± 8.7 and 125.6 ± 8.9 µm, respectively (p > 0.05). OPA and RVC are unchanged after triple intravitreal ranibizumab injections, indicating that this treatment does not significantly alter gross retina-choroidal vasculature and hemodynamics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  CAS  PubMed  Google Scholar 

  2. Resnikoff S, Pascolini D, Etya’ale D et al (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–851

    PubMed  PubMed Central  Google Scholar 

  3. Ferris FL 3rd, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640–1642

    Article  PubMed  Google Scholar 

  4. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606–2617

    Article  CAS  PubMed  Google Scholar 

  5. Kovach JL, Schwartz SG, Flynn HW et al (2012) Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol 2012:786870. doi:10.1155/2012/786870

    Article  PubMed  PubMed Central  Google Scholar 

  6. Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results: comparison of age-related macular degeneration treatments trials (catt) research group. Ophthalmology 119:1388–1398

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mori F, Konno S, Hikichi T et al (2001) Pulsatile ocular blood flow study: decreases in exudative age related macular degeneration. Br J Ophthalmol 85:531–533

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hoffmann EM, Grus FH, Pfeiffer N (2004) Intraocular pressure and ocular pulse amplitude using dynamic contour tonometry and contact lens tonometry. BMC Ophthalmol 23:4

    Article  Google Scholar 

  9. Punjabi OS, Kniestedt C, Stamper RL et al (2006) Dynamic contour tonometry: principle and use. Clin Exp Ophthalmol 34:837–840

    Article  Google Scholar 

  10. Rechtman E, Stalmans I, Glovinsky J et al (2011) The effect of intravitreal bevacizumab (Avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration. Clin Ophthalmol 5:37–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wickremasinghe SS, Xie J, Guymer RH et al (2012) Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. Eye 26:958–966

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mendrinos E, Mangioris G, Papadopoulou DN et al (2013) Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Acta Ophthalmol 91:184–190

    Article  Google Scholar 

  13. Wickremasinghe SS, Guymer RH, Wong TY et al (2012) Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Clin Exp Ophthalmol 40:59–66

    Article  Google Scholar 

  14. Gaudreault J, Fei D, Rusit J et al (2005) Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726–733

    Article  PubMed  Google Scholar 

  15. Chen Y, Han F (2012) Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Ther Clin Risk Manag 8:343–351

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850–857

    Article  CAS  PubMed  Google Scholar 

  17. Chen SJ, Cheng CY, Lee AF et al (2001) Pulsatile ocular blood flow in asymmetric exudative age related macular degeneration. Br J Ophthalmol 85:1411–1415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sandhu R, Sivaprasad S, Shah SP et al (2007) Pulsatile ocular blood flow in asymmetric age-related macular degeneration. Eye (Lond) 21:506–511

    CAS  Google Scholar 

  19. Pemp B, Schmetterer L (2008) Ocular blood flow in diabetes and age-related macular degeneration. Can J Ophthalmol 43:295–301

    Article  PubMed  Google Scholar 

  20. Bonnin P, Pournaras JA, Lazrak Z et al (2010) Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin(®)) in neovascular age-related macular degeneration. Acta Ophthalmol 88:641–645

    Article  CAS  PubMed  Google Scholar 

  21. Hosseini H, Lotfi M, Esfahani MH et al (2012) Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina 32:967–971

    Article  CAS  PubMed  Google Scholar 

  22. Good TJ, Kimura AE, Mandava N et al (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114

    Article  PubMed  Google Scholar 

  23. Adelman RA, Zheng Q, Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26:105–110

    Article  CAS  PubMed  Google Scholar 

  24. Sobacı G, Güngör R, Özge G (2013) Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol 6:211–215

    PubMed  PubMed Central  Google Scholar 

  25. Jaffe GJ, Martin DF, Toth CA et al (2013) Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:1860–1870

    Article  PubMed  PubMed Central  Google Scholar 

  26. Panos GD, Gatzioufas Z, Petropoulos IK et al (2013) Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration. Drug Des Devel Ther 7:565–569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Pierro L, Zampedri E, Milani P et al (2012) Spectral domain OCT versus time domain OCT in the evaluation of macular features related to wet age-related macular degeneration. Clin Ophthalmol 6:219–223

    PubMed  PubMed Central  Google Scholar 

  28. Semeraro F, Morescalchi F, Parmeggiani F et al (2011) Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Curr Vasc Pharmacol 9:629–646

    Article  CAS  PubMed  Google Scholar 

  29. Costagliola C, Agnifili L, Arcidiacono B et al (2012) Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 12:1299–1313

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology Department, Pamukkale University, Denizli, 20070, Turkey

    Gökhan Pekel, Semra Acer, Ebru Nevin Çetin, Ramazan Yağcı & Alper Kaşıkçı

  2. Tatvan State Hospital, Eye Clinic, Bitlis, Turkey

    Ali Çevik

Authors
  1. Gökhan Pekel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Semra Acer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ebru Nevin Çetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ramazan Yağcı
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alper Kaşıkçı
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ali Çevik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gökhan Pekel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pekel, G., Acer, S., Çetin, E.N. et al. Ocular pulse amplitude and retinal vessel caliber changes after intravitreal ranibizumab. Int Ophthalmol 35, 657–662 (2015). https://doi.org/10.1007/s10792-014-9991-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-014-9991-z

Keywords

Search

Navigation